Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by jocotocoon Nov 03, 2010 11:19am

297 Views

Post# 17651079

RE: RE: Potential fly in the ointment?

As for the rig. The service rig could cost 50,000 per day. The Nabors rig was probably around 500,000 per day so as a share holder I'm happy with the saving . Use the money and rig for drilling the next well...which we will have to wait because That Nabors rig is in a long term lease with Petrobras[?] We got it because of the mutual friends between the two companies who worked out a window for QEI to get into the game. PDP drilled a similar well last year with a lesser rig and look what happened to them. Burnt thru several million dollars.
Cheers
Jocotoco

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity